MA56540A - Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone - Google Patents

Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone

Info

Publication number
MA56540A
MA56540A MA056540A MA56540A MA56540A MA 56540 A MA56540 A MA 56540A MA 056540 A MA056540 A MA 056540A MA 56540 A MA56540 A MA 56540A MA 56540 A MA56540 A MA 56540A
Authority
MA
Morocco
Prior art keywords
ethenone
dihydroisoquinolin
methylbutyl
dichlorophenyl
hydroxymethyl
Prior art date
Application number
MA056540A
Other languages
English (en)
Inventor
Kevin Paul Cole
Neil John Kallman
Nicholas Andrew Magnus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA56540A publication Critical patent/MA56540A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
MA056540A 2019-06-18 2020-06-11 Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone MA56540A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962862805P 2019-06-18 2019-06-18

Publications (1)

Publication Number Publication Date
MA56540A true MA56540A (fr) 2022-04-27

Family

ID=71950727

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056540A MA56540A (fr) 2019-06-18 2020-06-11 Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone

Country Status (17)

Country Link
US (1) US12454512B2 (fr)
EP (1) EP3986867B1 (fr)
JP (3) JP7354303B2 (fr)
KR (1) KR102642754B1 (fr)
CN (2) CN113993849B (fr)
AR (1) AR119123A1 (fr)
AU (1) AU2020297336B2 (fr)
CA (2) CA3219063A1 (fr)
EA (1) EA202193105A1 (fr)
ES (1) ES2960876T3 (fr)
IL (1) IL288521B2 (fr)
MA (1) MA56540A (fr)
MX (1) MX2021015326A (fr)
SA (1) SA521431128B1 (fr)
TW (2) TWI825323B (fr)
WO (1) WO2020257043A1 (fr)
ZA (1) ZA202109907B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
WO2026022198A1 (fr) 2024-07-25 2026-01-29 UCB Biopharma SRL Procédé de préparation de 2-(3,5-dichloro-1-méthyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxyméthyl)-5-(1-hydroxy-1-méthyl-éthyl)-1-méthyl-3,4-dihydro-1h-isoquinoléin-2-yl]éthanone monohydrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30244A1 (es) * 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
US9525293B2 (en) * 2011-12-30 2016-12-20 Makita Corporation Battery charger having angled wall in battery receiving opening, and battery pack charging system and cordless power tool system including same
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物

Also Published As

Publication number Publication date
CN120058628A (zh) 2025-05-30
JP7354303B2 (ja) 2023-10-02
IL288521B1 (en) 2024-10-01
MX2021015326A (es) 2022-01-18
ES2960876T3 (es) 2024-03-07
KR20220008902A (ko) 2022-01-21
CA3219030A1 (fr) 2020-12-24
JP2025066724A (ja) 2025-04-23
JP2022537380A (ja) 2022-08-25
WO2020257043A1 (fr) 2020-12-24
EA202193105A1 (ru) 2022-03-11
TWI825323B (zh) 2023-12-11
JP7615257B2 (ja) 2025-01-16
IL288521A (en) 2022-01-01
US20220242826A1 (en) 2022-08-04
EP3986867A1 (fr) 2022-04-27
ZA202109907B (en) 2025-01-29
CA3143463A1 (fr) 2020-12-24
CA3143463C (fr) 2025-06-10
AU2020297336A1 (en) 2022-01-06
IL288521B2 (en) 2025-02-01
CA3219063A1 (fr) 2020-12-24
TW202114992A (zh) 2021-04-16
TW202408997A (zh) 2024-03-01
CN113993849B (zh) 2025-03-07
AU2020297336B2 (en) 2023-08-10
JP2023179519A (ja) 2023-12-19
EP3986867B1 (fr) 2023-09-13
TWI843678B (zh) 2024-05-21
CN113993849A (zh) 2022-01-28
BR112021025532A2 (pt) 2022-04-19
SA521431128B1 (ar) 2024-04-28
KR102642754B1 (ko) 2024-03-05
US12454512B2 (en) 2025-10-28
AR119123A1 (es) 2021-11-24

Similar Documents

Publication Publication Date Title
EP3941924A4 (fr) Technologies utiles pour la préparation d'oligonucléotides
MA56540A (fr) Procédés et intermédiaires pour la préparation de 2-(2,6-dichlorophényle))-1-[(1s,3r)-3-(hydroxyméthyl)-5-(3-hydroxy-3-méthylbutyl)-1-méthyl-3,4-dihydroisoquinolin-2(1)-yl]éthénone
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
PH12012500809A1 (en) Methods and compositions for treating cancer
GEP20247638B (en) Pharmaceutical combination of prmt5 inhibitors
EP3873905A4 (fr) Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
MA34047B1 (fr) Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EA201070012A1 (ru) МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ
EP3981399A4 (fr) Comprimé solide pour voie orale comprenant un inhibiteur de tyrosine kinase de bruton et son procédé de préparation
MA30604B1 (fr) Agonistes de ep2
EP4192455A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la neurodégénérescence
EP3819284A4 (fr) Catalyseur pour la préparation de 1,2-pentanediol et procédé de préparation de 1,2-pentanediol l'utilisant
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
HK1255438A1 (zh) 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
MX2023010540A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia.
EP3897651A4 (fr) Découverte d'inhibiteurs de la bd oxydase pour le traitement de maladies mycobactériennes
EP4021920A4 (fr) Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EA202191904A1 (ru) Фармацевтические композиции, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и способы их применения
WO2020165838A9 (fr) Procédés de traitement de la douleur de surface oculaire
EP3927689A4 (fr) Procédés de préparation de (3r,4r)-1-benzyl-n,4-diméthylpipéridin-3-amine ou d'un sel de celui-ci et procédés de préparation de tofacitinib l'utilisant
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
MA56550A (fr) Formes solides de tert-butyl (s)-2-((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo -2, 5-diazaspiro[3,4]octane-5-carboxylate et leurs procédés de préparation